Sodium-glucose cotransporter 2 (SGLT2) inhibitors have transformed the landscape of type 2 diabetes management by providing not only effective glycemic control but also cardiovascular and renal benefits. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.